The Lactobacillus Casei probiotic strain has been used in food and dietary supplements since 1995 and is one of the best documented probiotic Lactobacillus strains. It has been described in over 90 scientific publications and more than 20 clinical studies.
The US Food and Drug Administration (FDA) has designated the Lactobacillus Casei strain as Generally Recognized As Safe (GRAS). In addition, Lactobacillus Casei has been reviewed and granted New Dietary Ingredient (NDI) status by US FDA. In Europe, Lactobacillus Casei has been granted Qualified Presumption of Safety (QPS) status since 2007 by the European Food Safety Authority (EFSA) – a status granted on species level.
Substantial clinical data indicate that the Lactobacillus Casei probiotic strain may have beneficial effects in the gastrointestinal and immune areas:
- May enhance the immune response
- May reduce the incidence of upset stomach
- May reduce the duration of running nose, cough and sore throat as well as discomforts usually experienced during the cold season, e.g. high body temperature accompanied by body aches, etc.
- Jespersen et al., Effect of Lactobacillus paracasei subsp. paracasei, L. casei 431 on immune response to inﬂuenza vaccination and upper respiratory tract infections in healthy adult volunteers: a randomized, double blind, placebo-controlled, parallel-group study, Am J Clin Nutr 2015;101:1188–96.
- Rizzaedini et al., Evaluation of the immune beneﬁts of two probiotic strains Biﬁdobacterium animalis ssp. lactis, BB-12 ® and Lactobacillus paracasei ssp. paracasei, L. casei 431 ® in an inﬂuenza vaccination model: a randomised, double-blind, placebo-controlled study, British Journal of Nutrition 2012;107: 876–84.
- De Vrese et al., Probiotic bacteria stimulate virus-specific neutralizing antibodies following a booster polio vaccination, Eur J Nutr 2005;44:406–413.